Navigation Links
Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
Date:10/16/2007

Results presented today at American College of Gastroenterology's Annual Meeting

COLLEGE PARK, Md., Oct. 16 /PRNewswire-USNewswire/ -- A clinical trial conducted by University of Maryland School of Medicine researchers and CSA Medical Inc. may yield a breakthrough treatment for pre-cancerous and cancerous diseases of the esophagus.

Results of the trial, supported by the Maryland Industrial Partnerships Program (MIPS), show that a technique called CryoSpray Ablation (TM) (CSA) can reduce and often eliminate pre-cancerous and cancerous lesions in patients, including those with Barrett's esophagus, a precursor to cancer involving esophageal lesions created by chronic acid reflux.

Trial results will be presented today at the American College of Gastroenterology's Annual Scientific Meeting in Philadelphia by Bruce Greenwald, M.D., associate professor of medicine at the University of Maryland School of Medicine, who was principal investigator of the study. The trial was conducted at the University of Maryland Medical Center in Baltimore.

"Esophageal cancer is as lethal as lung cancer and is one of the fastest growing cancers in the Western world right now," says Tim Askew, president and CEO of CSA Medical. "More than 6 million people in the U.S. have Barrett's esophagus, while 65 million people suffer from GastroEsophageal Reflux Disease (GERD), also called "acid reflux" or "heartburn". Approximately 350,000 persons with GERD develop more dangerous lesions, while 15,000 develop cancer annually, according to Askew.

CSA Medical's CryoSpray Ablation (TM) platform sprays liquid nitrogen on pre-cancerous or cancerous tissue, freezing and killing the malignant cells. Malignant cells die and slough off harmlessly, while normal tissue grows back.

"Most patients don't feel any significant pain and say it is a non-event," says Askew. "One patient said that finding parking was more difficult than the procedure. No other therapy for this type of cancer allows tissue to grow back naturally without the potential for scarring," Askew added.

Current treatments can be invasive, can require a hospital stay, and may produce severe side effects, including pain and a narrowing of the esophagus. CryoSpray Ablation (TM) is an outpatient procedure, with patients generally resuming normal activities the same or next day.

MIPS funding enabled CSA Medical to team with Dr. Greenwald in a clinical trial at the University of Maryland Medical Center. While MIPS projects typically last one year, CSA Medical's was so successful that the company stopped the trial within nine months and decided to pursue an expanded, multi-center trial.

In the past 18 months, CSA Medical has grown from one to 16 employees, raised $12 million in financing, acquired FDA clearance for its product, obtained certification to market its product in Europe, began a national, 20-center clinical trial, and commercially launched its CryoSpray Ablation (TM) product.

"The MIPS funding allowed us to validate our early clinical trial data in a major university hospital with a prominent physician," said Askew. "It was also a catalyst for our commercialization process."

More than 60 physicians around the country have been trained on CryoSpray Ablation (TM), while 16 leading hospitals are currently treating patients using the device. CSA Medical plans to add about 30 additional treatment centers in the next six months.

"I think CryoSpray Ablation will gain a firm foothold in gastroenterology for the destruction of cancer and precancerous lesions in the GI tract," says Dr. Greenwald. "It holds a unique position in its ability to treat non-flat lesions that other technologies are lacking."

CSA Medical plans to investigate CryoSpray Ablation (TM) for treating other diseases.

About MIPS (http://www.mips.umd.edu)

The MTECH Maryland Industrial Partnerships Program, an initiative of the A. James Clark School of Engineering's Maryland Technology Enterprise Institute, brings university innovation to the commercial sector by supporting university-based research projects to help Maryland companies develop technology-based products.

About CSA Medical (http://www.csamedical.com)

CSA Medical Inc. is a privately held medical technology company dedicated to pioneering CryoSpray Ablation of pre-cancerous and cancerous lesions in the gastrointestinal tract. The company's mission is to design, develop and distribute a highly versatile platform of affordable CryoSpray Ablation (CSA(TM)) products that are considered safe and effective by patients, providers and payers, worldwide.

About the University of Maryland School of Medicine (http://www.medschool.umaryland.edu)

Established in 1807, the University of Maryland School of Medicine is the fifth oldest - and first public - medical school in the nation. The School of Medicine is dedicated to providing excellence in biomedical education, basic and clinical research, quality patient care and service.

CONTACT: Eric Schurr

301-405-3889

schurr@umd.edu


'/>"/>
SOURCE Maryland Technology Enterprise Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. New Information on the Potential of Plasmin Shared at ISTH Congress
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
5. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
9. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
10. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
11. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):